Clinical trials: E Coli Infection
Infection by Human Papilloma Virus
Lot-to-Lot Consistency Clinical Trial of Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli)
To support international market access and comply with World Health Organization Prequalification requirements, this lot-to-lot consistency trial is planned for initiation.
- Trial name
- NCT07668271
- Testing
- 9-valent HPV vaccine (Cecolin 9)
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Gram-negative Bacteremia
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of…
- Trial name
- GOAT (NCT06080698)
- Testing
- Intravenous Antibiotics, Oral Antibiotics
- Where
- 11 sites in United States
- Volunteers
- 1,030 people
- Sponsor
- Johns Hopkins University
Shigella Sonnei Dysenteries
Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults
This is a research study about an experimental (investigational) oral inactivated whole cell Shigella flexneri 2a killed vaccine (Sf2aWC) and an adjuvant called dmLT.
- Trial name
- NCT03038243
- Testing
- Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT), Shigella flexneri 2a whole cell (Sf2aWC) vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- PATH
Urinary Tract Infections (UTIs), Catheter-Associated Urinary Tract Infections (CAUTIs)
Antibiofilm Activity of Chitosan Nanoparticles Against Uropathogenic Escherichia Coli
1. Isolation of uropathogenic Escherichia coli (UPEC) and determination of their Antimicrobial sensitivity Patterns. 2. Evaluation of biofilm-forming capacity of UPEC isolates. 3.
- Conditions
- Urinary Tract Infections (UTIs), Catheter-Associated Urinary Tract Infections (CAUTIs), Biofilm Formation by Uropathogenic Escherichia Coli (UPEC)
- Trial name
- NCT07482553
- Testing
- chitosan nanoparticles
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Assiut University
Malaria
Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults
Malaria has remained a major concern for the US military. During World War II, malaria was the leading cause of disease and non-battle injury with 500-700 men infected per day, resulting in 24,000 malaria-related casualties.(10)…
- Trial name
- NCT01540474
- Testing
- Group 1: 10 ug FMP012 with 2 ug GLA-SE, Group 2: 10 ug FMP012 with 5 ug GLA-SE, 50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Acute Pyelonephritis Without Severity Symptoms Due to ESBL-producing E.Coli
Efficacy and Pharmacokinetic/Pharmacodynamic Parameters of Cefoxitin in Women With Acute Pyelonephritis Without Severity Symptoms Due to Extended-spectrum β-lactamase Producing Escherichia Coli
Escherichia coli is the primary cause of urinary tract infections and Gram-negative bacteremia worldwide. Since the early years of the 21st century, E.coli has acquired a new mechanism of resistance to antibiotics: extended…
- Trial name
- FOXICOLI (NCT01820793)
- Testing
- Cefoxitin
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Human Papillomavirus Infection
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
This study is to evaluate the safety and tolerability profile of Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli) in healthy women ages 18-45
- Trial name
- NCT05680454
- Testing
- Recombinant Nonavalent (Types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia Coli), Recombinant nonavalent Human Papillomavirus (Types 6,11,16,18,31,33,45,52,58) Vaccine
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Hepatitis E, Hepatitis B
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)
This is a open label, randomized phase VI study, to assess the safety and immunogenicity of co-administration of Hepatitis E vaccine with Hepatitis B vaccine.
- Trial name
- NCT02584543
- Testing
- HEV vaccine, HBV vaccine
- Where
- China
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Healthy Volunteers
Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)
The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity.
- Trial name
- NCT06314880
- Testing
- Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose), Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease
A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS
Hemolytic Uremic Syndrome (HUS) is a foodborne disease which mainly affects children. It is caused by Escherichia coli bacteria, which release a toxin called Shiga toxin within the body.
- Conditions
- Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease, Hemolytic-Uremic Syndrome
- Trial name
- NCT05569746
- Testing
- INM004, SoC
- Where
- 16 sites in Argentina
- Volunteers
- 57 people
- Sponsor
- Inmunova S.A.
Positive E Coli Infections
Ampicillin-sulbactam Resistant E.Coli at UPMC
The information collected will optimize the management of patients with gram negative bacteremia. Approximately 300 patients with Gram negative bacteremia are cared for each year at UPMC-P.
- Trial name
- NCT00619580
- Where
- United States
- Sponsor
- University of Pittsburgh
Urinary Tract Infections
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation…
- Trial name
- NCT06702449
- Testing
- Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1
- Where
- 8 sites in United States, South Africa
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Escherichia Coli Infections
Detection of Biofilm Among Uropathogenic Escherichia Coli Clinical Isolates in Suez Canal University Hospitals
This descriptive cross-sectional study will beconducted in Suez Canal University Hospitals (SCUHs) in Ismailia, Egypt. The study aims to detect Escherichia coli biofilm producers to improve prognosis and treatment and reduce…
- Trial name
- NCT06252428
- Where
- Egypt
- Volunteers
- 47 people
- Sponsor
- Suez Canal University
Urinary Tract Infection
E. Coli 83972 Induced Asymptomatic Bacteriuria (ABU) in Patients With Recurrent Urinary Tract Infections (UTI)
This study tests the following hypothesis: Does induced asymptomatic bacteriuria (E. coli 83972) protect against symptomatic urinary tract infections in individuals with bladder emptying dysfunctions and prone to recurrent…
- Trial name
- NCT00927316
- Testing
- E. coli 83972
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Region Skane
Urinary Tract Infection
Cranberry for UTI Prevention in Residents of Long Term Care Facilities
Urinary tract infections (UTIs) affect over 7 million men and women per year and cost the health care industry over 1 billion dollars annually.
- Trial name
- PACS (NCT00596635)
- Testing
- Once Daily Cranberry Capsule, Twice Daily Cranberry Capsules
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Yale University
Cervical Intraepithelial Neoplasia, Cervical Cancer
A Bridging Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls
This is a bridging trial of the recombinant HPV 16/18 bivalent vaccine manufactured by Xiamen Innovax Biotech CO., LTD.The primary objective of this study is to evaluate the immunogenicity (type specific IgG antibody) and safety…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Vaginal Intraepithelial Neoplasia, Vulvar Intraepithelial Neoplasia
- Trial name
- NCT02562508
- Testing
- 3 doses of HPV 16/18 bivalent vaccine, 2 doses of HPV 16/18 bivalent vaccine
- Where
- China
- Volunteers
- 979 people, healthy volunteers welcome
- Sponsor
- Jun Zhang
Prostatitis, Escherichia Coli Infection
Oral Fosfomycin as Sequential Oral Treatment for Multidrug-Resistant Escherichia Coli in Acute Bacterial Prostatitis
FOS-PROST was a prospective, non-randomized, controlled phase IV clinical trial designed to evaluate the clinical and microbiological efficacy of oral fosfomycin trometamol as sequential antibiotic therapy in patients with acute…
- Trial name
- FOS-PROST (NCT07902427)
- Testing
- Fosfomycin Trometamol Salt, control group
- Where
- 7 sites in Spain
- Volunteers
- 88 people
- Sponsor
- Hospital Mutua de Terrassa
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E.
- Trial name
- HIKO-STEC (NCT05219110)
- Testing
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Where
- 26 sites in United States, Canada
- Volunteers
- 1,040 people
- Sponsor
- University of Calgary
Urinary Tract Infections
Cefuroxime Resistance in Pyelonephritis
Resistance to empirical antibiotic treatment has resulted in increased mortality and morbidity in serious infections caused by certain common resistant pathogens in the community.
- Trial name
- NCT04616352
- Testing
- Resistance to cefuroxime
- Where
- Colombia
- Volunteers
- 973 people
- Sponsor
- Universidad Nacional de Colombia
Escherichia Coli; Infection, Intestinal
Study of the Ecological and Evolutionary Dynamics of Escherichia Coli in the Digestive Commensal Flora
Escherichia coli (E. coli) poses a major public health problem. E. coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia.
- Trial name
- EVE (NCT05153824)
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris